See more : Tesla, Inc. (TSLA) Income Statement Analysis – Financial Results
Complete financial analysis of CBD Life Sciences Inc. (CBDL) income statement, including revenue, profit margins, EPS and key performance metrics. Get detailed insights into the financial performance of CBD Life Sciences Inc., a leading company in the Drug Manufacturers – Specialty & Generic industry within the Healthcare sector.
You may be interested
- Nykredit Invest Lange Obligationer KL (NYILO.CO) Income Statement Analysis – Financial Results
- ITV plc (ITVPF) Income Statement Analysis – Financial Results
- Oversea-Chinese Banking Corporation Limited (O39.SI) Income Statement Analysis – Financial Results
- Modern Dairies Limited (MODAIRY.BO) Income Statement Analysis – Financial Results
- Prime Drink Group Corp. (PRME.CN) Income Statement Analysis – Financial Results
CBD Life Sciences Inc. (CBDL)
Industry: Drug Manufacturers - Specialty & Generic
Sector: Healthcare
Website: https://lbcbioscienceinc.com
About CBD Life Sciences Inc.
CBD Life Sciences Inc. engages in the development and marketing a line of cannabidiol based organic products. Its cannabidiol based organic products include hemp drops, massage oils, recovery pain relief creams, anxiety and sleep solutions supplements, edibles, and a line of pet products. The company is based in Scottsdale, Arizona.
| Metric | 2023 | 2022 | 2021 | 2020 | 2019 | 2014 | 2013 | 2012 | 2011 |
|---|---|---|---|---|---|---|---|---|---|
| Revenue | 167.15K | 160.24K | 59.26K | 225.90K | 79.64K | 122.79K | 155.55K | 0.00 | 0.00 |
| Cost of Revenue | 197.75K | 440.50K | 207.51K | 438.13K | 43.00K | 0.00 | 0.00 | 0.00 | 0.00 |
| Gross Profit | -30.60K | -280.26K | -148.25K | -212.23K | 36.63K | 122.79K | 155.55K | 0.00 | 0.00 |
| Gross Profit Ratio | -18.31% | -174.90% | -250.18% | -93.95% | 46.00% | 100.00% | 100.00% | 0.00% | 0.00% |
| Research & Development | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| General & Administrative | 30.20K | 0.00 | 1.39K | 314.85 | 337.43 | 752.49K | 442.90K | 53.29K | 44.12K |
| Selling & Marketing | 11.34K | 0.00 | 4.41K | 30.00 | 111.54 | 108.00K | 17.48K | 6.46K | 8.02K |
| SG&A | 46.05K | 571.77K | 4.96M | 171.86K | 906.25K | 860.49K | 460.38K | 59.75K | 52.14K |
| Other Expenses | 0.00 | -7.78K | -17.86K | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Operating Expenses | 47.97K | 579.55K | 4.98M | 171.86K | 906.25K | 883.80K | 499.04K | 155.72K | 52.74K |
| Cost & Expenses | 245.72K | 1.02M | 5.19M | 609.99K | 949.26K | 883.80K | 499.04K | 155.72K | 52.74K |
| Interest Income | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 | 0.00 |
| Interest Expense | 0.00 | 0.00 | 0.00 | 69.91K | 0.00 | 15.27K | 23.50K | 0.00 | 0.00 |
| Depreciation & Amortization | 55.56K | 53.56K | 236.56K | 206.30K | 171.86K | 23.31K | 38.66K | 95.97K | 0.00 |
| EBITDA | -23.02K | -806.25K | -5.13M | -1.31M | -869.62K | -741.56K | -304.97K | -60.36K | -52.74K |
| EBITDA Ratio | -13.77% | -503.14% | -8,654.23% | -170.03% | -1,092.01% | -600.79% | -195.96% | 0.00% | 0.00% |
| Operating Income | -78.57K | -859.80K | -5.13M | -384.09K | -869.62K | -780.14K | -367.14K | -156.33K | -52.74K |
| Operating Income Ratio | -47.01% | -536.57% | -8,654.23% | -170.03% | -1,092.01% | -635.35% | -236.02% | 0.00% | 0.00% |
| Total Other Income/Expenses | 0.00 | -4.00 | -2.00 | -1.31M | 8.61K | -15.27K | -23.50K | 0.00 | 0.00 |
| Income Before Tax | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Income Before Tax Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| Income Tax Expense | 0.00 | 4.00 | -6.14K | -384.09 | -75.24 | 15.27K | 23.50K | 610.00 | 0.00 |
| Net Income | -78.57K | -859.80K | -5.13M | -1.69M | -861.01K | -780.14K | -367.14K | -156.33K | -52.74K |
| Net Income Ratio | -47.01% | -536.57% | -8,654.24% | -750.07% | -1,081.20% | -635.35% | -236.02% | 0.00% | 0.00% |
| EPS | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| EPS Diluted | 0.00 | 0.00 | 0.00 | 0.00 | -0.01 | -428.18 | -2.29K | -2.41K | -893.95 |
| Weighted Avg Shares Out | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
| Weighted Avg Shares Out (Dil) | 40.71B | 40.71B | 12.30B | 934.78M | 108.36M | 1.82K | 160.00 | 65.00 | 59.00 |
CBD Life Sciences, Inc. (CBDL) Reaches Unprecedented Heights With Explosive Growth and Strategic Expansion in 2024
"Record-breaking revenue, new market entries, and transformative partnerships highlight our path to increasing shareholder value and long-term growth." SCOTTSDALE, AZ / ACCESSWIRE / October 8, 2024 / Dear Shareholders, 2024 has been a banner year for CBD Life Sciences, Inc....
CBD Life Sciences, Inc. (CBDL) Launches First-of-Its-Kind CBD Horse Paste: A Veterinarian-Designed Solution for Equine Wellness
The annual economic impact of the equine industry is significant - involving some $300 billion dollars and 1.6 million full-time jobs. CBD Life Sciences' Groundbreaking Horse Paste is Set to Transform the Industry and Drive Explosive Growth SCOTTSDALE, AZ /...
CBD Life Sciences Inc. (CBDL) Targets Amazon Marketplace for Strategic Business Enhancements
With Amazon's market value increasing by more than $400 billion in 2024, CBD Life Sciences Inc. is poised for new revenue growth with top-selling CBD Pain Relief Roll-On and Pet Treats. SCOTTSDALE, AZ / ACCESSWIRE / October 1, 2024 /...
CBD Life Sciences Inc. (CBDL) Announces Record Revenue Increase of 1405.46% Since February 2024
The U.S. CBD consumer health market size was estimated at USD 7.81 billion in 2023 and is projected to surpass around USD 31.11 billion by 2033 at a CAGR of 14.79% from 2024 to 2033 SCOTTSDALE, AZ / ACCESSWIRE /...
CBD Life Sciences, Inc. (CBDL) Announces Expanding Revenue Stream With Walmart Marketplace
Walmart's market cap as of September 2024 is $635.50 billion, making it the 13th most valuable company in the world. This partnership offers CBD Life Sciences unprecedented exposure on a global retail platform.
CBD Life Sciences, Inc. Unveils Groundbreaking Nutritional Supplement Infused With Mushroom Extracts, Set to Drive Revenue and Revolutionize Wellness
Projected to increase company revenue by 20% in the first year, capitalizing on the booming $18 billion wellness market. SCOTTSDALE, AZ / ACCESSWIRE / September 17, 2024 / CBD Life Sciences, Inc. (CBDL), an innovative leader in the CBD wellness...
CBD Life Sciences, Inc. (CBDL) Unveils Mellow Mornings: A Revolutionary Nano CBD Coffee Creamer Set to Boost Revenue Amid Growing National Demand
SCOTTSDALE, AZ / ACCESSWIRE / September 4, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leader in the CBD industry, is excited to announce the launch of its latest innovation, Mellow Mornings, a nano CBD Coffee Creamer poised to...
CBD Life Sciences, Inc. (CBDL) Announces MOU With New York Dispensary, Poised for Significant Revenue Growth and Shareholder Value
The targeted acquisition is estimated to have a business value of approximately $10 million and projected 2024 gross revenues of up to $4.5 million SCOTTSDALE, AZ / ACCESSWIRE / August 29, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a...
CBD Life Sciences, Inc. Expands Footprint With Proposed Strategic Acquisition of Interest in Two New York Cannabis Dispensaries
The targeted acquisitions are estimated to have a business value of approximately $14 million SCOTTSDALE, AZ / ACCESSWIRE / August 27, 2024 / CBD Life Sciences, Inc. (OTC PINK:CBDL), a leading innovator in the CBD industry, is pleased to announce...
Vienna Vikings Football Team Signs Partnership Agreement With the CBD Vault
SCOTTSDALE, AZ / ACCESSWIRE / August 14, 2024 / CBD Life Sciences Inc. (OTC PINK:CBDL), including its wholly-owned subsidiary, The CBD Vault Inc., a leading innovator in the CBD industry, has announced that it has signed a partnership agreement with...
Source: https://incomestatements.info
Category: Stock Reports